News on U.S. government agencies, U.S. politics, companies doing business with U.S. federal government. Read U.S. national and local news. This site is not affiliated with United States Government.
(EMAILWIRE.COM, November 15, 2011 ) Houston, TX -- The Wall Street Journal recently reported that Takeda Pharmaceutical Company, the creator of Actos, experienced a decrease in profit due to lower-than-average Actos sales. The Type 2 diabetes drug has been under investigation for possible links to serious health complications such as bladder cancer. The discovery of this potential connection is thought to have an impact on the drop in sales.
The Food and Drug Administration is continuing to review data from their study and has already published several warnings regarding Actos use.
Takeda Pharmaceutical Company is one of the largest pharmaceutical companies in Japan and has offices in many countries including the United States. The Wall Street Journal reported that profit was down 4.8% from the previous year and year end projections have changed from ¥250 billion to ¥170 billion.
According to www.pharmatimes.com, Actos was previously the companyÂ’s highest selling drug, but sales have noticeably declined after the recent warnings in the United States and Europe.
About Williams Kherkher
Williams Kherkher is a mass-tort law firm based in Houston, Texas, offering legal assistance to clients nationwide. The firm handles a variety of cases, including those involving personal injury law, mesothelioma, and defective pharmaceuticals. For more information about Actos lawsuit options, clinical trials, and your rights as a victim, visit the website of the Actos attorneys at www.actoslawsuitcounsel.com.
Contact:
Williams Kherkher
8441 Gulf Freeway, Suite 600
Houston, TX. 77017
800-761-3187
(EMAILWIRE.COM, November 15, 2011 ) Houston, TX -- The Wall Street Journal recently reported that Takeda Pharmaceutical Company, the creator of Actos, experienced a decrease in profit due to lower-than-average Actos sales. The Type 2 diabetes drug has been under investigation for possible links to serious health complications such as bladder cancer. The discovery of this potential connection is thought to have an impact on the drop in sales.
The Food and Drug Administration is continuing to review data from their study and has already published several warnings regarding Actos use.
Takeda Pharmaceutical Company is one of the largest pharmaceutical companies in Japan and has offices in many countries including the United States. The Wall Street Journal reported that profit was down 4.8% from the previous year and year end projections have changed from ¥250 billion to ¥170 billion.
According to www.pharmatimes.com, Actos was previously the companyÂ’s highest selling drug, but sales have noticeably declined after the recent warnings in the United States and Europe.
About Williams Kherkher
Williams Kherkher is a mass-tort law firm based in Houston, Texas, offering legal assistance to clients nationwide. The firm handles a variety of cases, including those involving personal injury law, mesothelioma, and defective pharmaceuticals. For more information about Actos lawsuit options, clinical trials, and your rights as a victim, visit the website of the Actos attorneys at www.actoslawsuitcounsel.com.
Contact:
Williams Kherkher
8441 Gulf Freeway, Suite 600
Houston, TX. 77017
800-761-3187
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:
(EMAILWIRE.COM, November 15, 2011 ) Houston, TX -- The Wall Street Journal recently reported that Takeda Pharmaceutical Company, the creator of Actos, experienced a decrease in profit due to lower-than-average Actos sales. The Type 2 diabetes drug has been under investigation for possible links to serious health complications such as 